ESMO GI 2017

Prof Gruenberger talks with ecancer at ESMO GI 2017 about the diagnosis and treatment of cholangiocarcinoma dependant on the variables of the disease. He goes onto discuss the surgical options for different entities of cholangiocarcinoma. He then continues to review a recent phase III trial that found that giving adjuvant capecitabine was beneficial in terms of overall survival for patients.

Dr Philip talks with ecancer at ESMO GI 2017 about new drugs that are on the horizon for pancreatic cancer and his views on development. He discusses ongoing clinical trials and what he believes may be the outcomes of those trials. Dr Philip goes on to talk about the need to target the microenvironment and stromal cells of a tumour and the DNA repair pathways.

Prof Regula talks with ecancer at ESMO GI 2017 about the recommendations for surveillance after surgery to remove adenomas. He goes on to discuss the differences in recommendations and guidelines depending on geographic location. Prof Regula then discusses the need to assess all recommendations coming out of trails in order to get the best care possible for patients.

Dr Di Nicolantonio talks with ecancer at ESMO GI 2017 about acquired resistance to EGFR antibodies in colorectal cancer and how this is managed. She also discusses how to act upon some of the molecular mechanisms of drug resistance in colorectal cancer, and the clincal implications behind this research.

Dr Ibnshamsah talks with ecancer at ESMO GI 2017 about gastrointestinal stromal tumour and the retrospective study looking into the decisions being made for adjuvant therapy according to the armed forces institute of pathology’s criteria for risk stratification.

Dr Chau talks with ecancer at ESMO GI 2017 about the optimal approach to neo-adjuvant/adjuvant treatment in gastric cancer in 2017. He discusses the uses multi-modality treatments such as pre-operative treatments and post-operative treatments, and the survivorship outcomes within different regions.

Prof Lordick talks with ecancer at ESMO GI 2017 about news and new evolutions for neoadjuvant and adjuvant treatment of oesophageal cancer. He discusses the new ESMO guidelines for oesophageal cancer and talks about the need to separate recommendations for oesophageal cancer and adenocarcinoma because of the different biology of the diseases.

Prof Mariette talks with ecancer at ESMO GI 2017 about a phase III randomised trial, looking at minimally invasive oesophagectomy and the benefits of this procedure over open oesophagectomy. He goes on to outline the benefits of using laparoscopic gastric mobilisation and open thoracotomy over the standard opened abdominal and open thoracic approach.

Dr Grothey talks with ecancer at ESMO GI 2017 about what the future holds for GI oncologists. He states that he believes that the way that oncologists interact with patients will change to allow patients to have access to medical information and their care throughout the entire process. Dr Grothey believes that there will be a device created to transmit information, continuously, between patient and medical professional, allowing treatments to be modified early if needed. Dr Grothey goes on to discuss immunotherapies and how he thinks there will be inroads made into treating cancers that are not currently immunogenic. He believes that immunotherapy will be used as first line treatment. Dr Grothey then talks about how he believes that diagnostic tools will be developed to allow circulating markers to be more evident through the diagnostic process.

Dr Grothey talks with ecancer at ESMO GI 2017 about the value of sidedness in colon cancer. He discusses how the location of the tumour can affect how the cancer responds to different drugs and treatments. He goes on to discuss his thoughts on drug prescription, dependant on tumour location.

Prof D’Hoore talks to ecancer at ESMO GI 2017 about the implementation of a wait and see program for rectal cancer, and the possible pitfalls. He discusses the use of endoscopy, imaging and PET scanning for diagnosis, and the challenges of avoiding radical surgery and opting for a "watch and wait" protocol. Finally, he discusses the highlights of ESMO GI 2017.